MedTrace Logo

Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia

NCT01226303 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2017-01-26

No results posted yet for this study

Summary

This study is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR positive for the PML-RARα transcript or rarer retinoid sensitive subtypes (i.e. NPM-RAR-alpha, NuMA-RARalpha) and less than 21 years of age (for AIEOP, see appendix A).

Conditions

  • Acute Promyelocytic Leukemia

Interventions

DRUG

ATRA

see the protocol

DRUG

ATRA + IDA

see the protocol

Sponsors & Collaborators

  • Associazione Italiana Ematologia Oncologia Pediatrica

    lead OTHER

Principal Investigators

  • Annamaria Testi, Dr · Associazione Italiana Ematologia Oncologia Pediatrica

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2017-06-30
Completion
2018-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226303 on ClinicalTrials.gov